PURPOSE: Tamoxifen was approved for breast cancer risk reduction in high-risk women based on the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial (P-1:BCPT), which showed 50% fewer breast cancers with tamoxifen versus placebo, supporting tamoxifen's efficacy in preventing breast cancer. Poor metabolizing CYP2D6 variants are currently the subject of intensive scrutiny regarding their impact on clinical outcomes in the adjuvant setting. Our study extends to variants in a wider spectrum of tamoxifen-metabolizing genes and applies to the prevention setting. METHODS: Our case-only study, nested within P-1:BCPT, explored associations of polymorphisms in estrogen/tamoxifen-metabolizing genes with responsiveness to preventive tamoxifen. Thirty-nine candidate polymorphisms in 17 candidate genes were genotyped in 249 P-1:BCPT cases. RESULTS: CVP2D6_C1111T, individually and within a CYP2D6 haplotype, showed borderline significant association with treatment arm. Path analysis of the entire tamoxifen pathway gene network showed that the tamoxifen pathway model was consistent with the pattern of observed genotype variability within the placebo-arm dataset. However, correlation of variations in genes in the tamoxifen arm differed significantly from the predictions of the tamoxifen pathway model. Strong correlations between allelic variation in the tamoxifen pathway at CYP1A1-CYP3A4, CYP3A4-CYP2C9, and CYP2C9-SULT1A2, in addition to CYP2D6 and its adjacent genes, were seen in the placebo-arm but not the tamoxifen-arm. In conclusion, beyond reinforcing a role for CYP2D6 in tamoxifen response, our pathway analysis strongly suggests that specific combinations of allelic variants in other genes make major contributions to the tamoxifen-resistance phenotype.
PURPOSE:Tamoxifen was approved for breast cancer risk reduction in high-risk women based on the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial (P-1:BCPT), which showed 50% fewer breast cancers with tamoxifen versus placebo, supporting tamoxifen's efficacy in preventing breast cancer. Poor metabolizing CYP2D6 variants are currently the subject of intensive scrutiny regarding their impact on clinical outcomes in the adjuvant setting. Our study extends to variants in a wider spectrum of tamoxifen-metabolizing genes and applies to the prevention setting. METHODS: Our case-only study, nested within P-1:BCPT, explored associations of polymorphisms in estrogen/tamoxifen-metabolizing genes with responsiveness to preventive tamoxifen. Thirty-nine candidate polymorphisms in 17 candidate genes were genotyped in 249 P-1:BCPT cases. RESULTS: CVP2D6_C1111T, individually and within a CYP2D6 haplotype, showed borderline significant association with treatment arm. Path analysis of the entire tamoxifen pathway gene network showed that the tamoxifen pathway model was consistent with the pattern of observed genotype variability within the placebo-arm dataset. However, correlation of variations in genes in the tamoxifen arm differed significantly from the predictions of the tamoxifen pathway model. Strong correlations between allelic variation in the tamoxifen pathway at CYP1A1-CYP3A4, CYP3A4-CYP2C9, and CYP2C9-SULT1A2, in addition to CYP2D6 and its adjacent genes, were seen in the placebo-arm but not the tamoxifen-arm. In conclusion, beyond reinforcing a role for CYP2D6 in tamoxifen response, our pathway analysis strongly suggests that specific combinations of allelic variants in other genes make major contributions to the tamoxifen-resistance phenotype.
Entities:
Keywords:
Breast cancer; breast cancer risk; chemoprevention; genomic; pathway analysis; tamoxifen resistance
Authors: Lukas A Hefler; Christoph Grimm; Tilmann Lantzsch; Dieter Lampe; Heinz Koelbl; Antje Lebrecht; Georg Heinze; Clemens Tempfer; Alexander Reinthaller; Robert Zeillinger Journal: Breast Cancer Res Treat Date: 2006-03-15 Impact factor: 4.872
Authors: Vincent O Dezentjé; Henk-Jan Guchelaar; Johan W R Nortier; Cornelis J H van de Velde; Hans Gelderblom Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 12.531
Authors: C B Ambrosone; J L Freudenheim; S Graham; J R Marshall; J E Vena; J R Brasure; R Laughlin; T Nemoto; A M Michalek; A Harrington Journal: Cancer Res Date: 1995-08-15 Impact factor: 12.701
Authors: K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun Journal: Proc Natl Acad Sci U S A Date: 2001-01-02 Impact factor: 11.205
Authors: Pia Wegman; Linda Vainikka; Olle Stål; Bo Nordenskjöld; Lambert Skoog; Lars-Erik Rutqvist; Sten Wingren Journal: Breast Cancer Res Date: 2005-01-28 Impact factor: 6.466
Authors: Matthew P Goetz; Daniel J Schaid; D Lawrence Wickerham; Stephanie Safgren; Taisei Mushiroda; Michiaki Kubo; Anthony Batzler; Joseph P Costantino; Victor G Vogel; Soonmyung Paik; Erin E Carlson; David A Flockhart; Norman Wolmark; Yusuke Nakamura; Richard M Weinshilboum; James N Ingle; Matthew M Ames Journal: Clin Cancer Res Date: 2011-08-31 Impact factor: 12.531
Authors: Ewa E Hennig; Magdalena Piatkowska; Jakub Karczmarski; Krzysztof Goryca; Elzbieta Brewczynska; Radoslaw Jazwiec; Anna Kluska; Robert Omiotek; Agnieszka Paziewska; Michal Dadlez; Jerzy Ostrowski Journal: BMC Cancer Date: 2015-08-01 Impact factor: 4.430
Authors: Ana Fernández-Santander; María Gaibar; Apolonia Novillo; Alicia Romero-Lorca; Margarita Rubio; Luis Miguel Chicharro; Armando Tejerina; Fernando Bandrés Journal: PLoS One Date: 2013-07-29 Impact factor: 3.240
Authors: Matteo Lazzeroni; Davide Serrano; Barbara K Dunn; Brandy M Heckman-Stoddard; Oukseub Lee; Seema Khan; Andrea Decensi Journal: Breast Cancer Res Date: 2012-10-29 Impact factor: 6.466
Authors: Davide Serrano; Matteo Lazzeroni; Sara Gandini; Debora Macis; Harriet Johansson; Jennifer Gjerde; Ernst Lien; Irene Feroce; Giancarlo Pruneri; Maria Sandri; Fabio Bassi; Fabricio Brenelli; Alberto Luini; Massimiliano Cazzaniga; Clara Varricchio; Aliana Guerrieri-Gonzaga; Andrea DeCensi; Bernardo Bonanni Journal: Breast Cancer Res Date: 2013-06-20 Impact factor: 6.466